Skip to main content
. 2015 Jul 30;112(33):E4600–E4609. doi: 10.1073/pnas.1513433112

Fig. S3.

Fig. S3.

Role of Nanog expression in the regulation of other pluripotency factors and clinical outcome for ER (+) breast cancer patients treated with chemotherapy. (A) Total cellular RNA from MDA-MB-231 subclones stably transfected with NTC or Nanog shRNA vector were subjected to RT-qPCR to analyze Sox2 and Oct4 mRNA expression. The results were normalized to NTC (mean ± SEM; n = 3). ***P < 0.001 vs. NTC. (B) Kaplan–Meier analysis of relapse-free survival was performed based on clinical and molecular data from 173 ER (+) breast cancer patients who received chemotherapy. The patients were stratified according to Nanog mRNA levels in the primary tumor. High, Nanog mRNA greater than the median; Low, Nanog mRNA less than the median. The P value (log-rank test) and hazard ratio (HR) are shown.